V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220009653 | 220003942 | 1.77 | 112 | Curative (C) | 2016-08-01 | 2016-09-29 | Dacarbazine | N | N | 220026058 | BOSUTINIB |
| 220009655 | 220003944 | null | 84.4 | Curative (C) | null | 2019-03-08 | IPILIMUMAB + NIVOLUMAB | null | null | 220026216 | METHOTREXATE INTRATHECAL |
| 220009656 | 220003945 | 0.01 | 0 | Curative (C) | 2016-07-20 | 2016-07-20 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | null | 220026305 | METHOTREXATE INTRATHECAL |
| 220009657 | 220003946 | null | 51 | Curative (C) | 2016-05-02 | 2016-05-02 | AML LI-1 Trial | N | N | 220026351 | FBC |
| 220009658 | 220003947 | 0 | 76.8 | Palliative (P) | 2017-01-24 | 2017-01-26 | IPO | N | N | 220026376 | IPILIMUMAB |
| 220009659 | 220003948 | 1.64 | 80.6 | Curative (C) | null | 2016-06-02 | LENALIDOMIDE | N | N | 220026615 | CYTARABINE + MITOXANTRONE |
| 220009660 | 220003948 | null | null | Curative (C) | 2018-03-13 | 2018-04-11 | Fludarabine + Melphalan RIC Allo | 2 | N | 220026615 | TRIPLE INTRATHECAL |
| 220009661 | 220003948 | 1.49 | 80 | Palliative (P) | 2018-08-12 | 2018-08-12 | IPILIMUMAB + NIVOLUMAB | 2 | null | 220026615 | ENZALUTAMIDE |
| 220009662 | 220003949 | 1.77 | 80.1 | Curative (C) | 2015-06-17 | 2015-06-17 | Capecitabine (14 day) + Irinotecan | Y | N | 220026742 | BOSUTINIB |
| 220009663 | 220012108 | 1.65 | null | Palliative (P) | null | 2014-01-17 | Vemurafenib | null | null | 220026850 | METHOTREXATE INTRATHECAL |
| 220009664 | 220016553 | 1.61 | 112 | Disease modification (D) | 2017-11-01 | 2017-11-02 | PONATINIB | 02 | N | 220027021 | CYTARABINE INTRATHECAL |
| 220009665 | 220016553 | 1.71 | 83.8 | Disease modification (D) | 2013-06-06 | 2016-06-24 | LANREOTIDE | N | N | 220027021 | BUSULPHAN |
| 220009666 | 220016553 | null | null | Curative (C) | null | 2018-10-04 | OCTREOTIDE | null | null | 220027021 | CARBOPLATIN + RT |
| 220009667 | 220020547 | null | 54.4 | Curative (C) | 2016-08-12 | 2016-08-21 | Arsenic Triox + Tretinoin Ind W1-4 | 1 | null | 220027233 | FBC |
| 220009668 | 220003950 | null | 70 | Disease modification (D) | 2018-03-25 | 2018-03-26 | FCR Oral - Cycle 1 | Y | N | 220027282 | QUASAR 2 TRIAL |
| 220009669 | 220003951 | 1.56 | 49 | Curative (C) | null | 2017-03-29 | Triple / Double Intrathecal Therapy | N | N | 220027320 | FLUDARABINE + MELPHALAN |
| 220009670 | 220003952 | 1.03 | 76.5 | Palliative (P) | 2017-07-06 | 2017-07-27 | Capecitabine + Streptozocin | N | null | 220027339 | CAPECITABINE + CISPLATIN + EPIRUBICIN |
| 220009671 | 220003952 | 1.33 | null | null | 2018-03-06 | 2018-03-16 | Arsenic trioxide | N | N | 220027339 | CTD |
| 220009672 | 220003953 | 1.6 | 60.5 | Disease modification (D) | 2017-01-29 | 2017-01-30 | Alemtuzumab cond (RI ALLO CAMP100) | 02 | N | 220027415 | BOSUTINIB |
| 220009673 | 220012110 | 1.78 | 76.15 | Not known (9) | 2018-05-24 | 2018-05-24 | LIPOSOMAL DAUNORUBICIN | N | N | 220027488 | IDARUBICIN |
| 220009674 | 220003954 | 2 | 66 | Disease modification (D) | 2016-05-24 | 2016-05-31 | DABRAFENIB + TRAMETINIB | 01 | N | 220027500 | DABRAFENIB + TRAMETINIB |
| 220009675 | 220003955 | 1.86 | 55.2 | Palliative (P) | null | 2015-12-08 | CARBOPLATIN + RT | 2 | N | 220027517 | DACARBAZINE |
| 220009676 | 220003955 | 1.76 | null | Adjuvant (A) | null | 2018-01-04 | Cytarabine intrathecal | N | N | 220027517 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 220009677 | 220003956 | 1.73 | 66.1 | Curative (C) | 2017-01-20 | 2017-01-20 | UKALL14- Ph 1 Induction | 2 | N | 220027666 | IDARUBICIN + MITOXANTRONE + TRETINOIN |
| 220009678 | 220012112 | 1.78 | 9.7 | null | null | 2017-11-01 | CETUXIMAB | N | N | 220027668 | FLUOROURACIL |
| 220009679 | 220003957 | 1.77 | 0 | Curative (C) | 2017-02-11 | 2017-02-11 | Paclitaxel 80mg/m2 day 1 8 15 | 01 | N | 220027863 | NHL 2003 |
| 220009680 | 220003958 | 1.57 | 80.8 | Disease modification (D) | 2014-09-04 | 2014-09-04 | DABRAFENIB + TRAMETINIB | 02 | Y | 220027883 | CYTARABINE INTRATHECAL |
| 220009681 | 220012113 | null | null | Curative (C) | 2014-02-09 | 2014-02-10 | OCTREOTIDE | N | N | 220027954 | DOXORUBICIN |
| 220009682 | 220016554 | 1.78 | 71.9 | Curative (C) | 2018-06-21 | 2018-06-21 | SPIRIT 2 TRIAL | 02 | Y | 220027990 | CVP R |
| 220009683 | 220003959 | 1.66 | 75 | Curative (C) | 2017-08-25 | 2017-09-24 | IDARUBICIN + MITOXANTRONE + Tretinoin | N | N | 220028042 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220009684 | 220003960 | 1.77 | 88.7 | Neo-adjuvant (N) | 2014-03-16 | 2014-03-17 | Cisplatin + Pemetrexed | N | N | 220028218 | DOCETAXEL |
| 220009685 | 220003961 | null | null | null | 2018-05-01 | 2018-05-08 | CETUXIMAB | N | null | 220028306 | CHLORAMBUCIL + OBINUTUZUMAB |
| 220009686 | 220003962 | null | null | null | 2014-08-14 | 2014-08-17 | Capecitabine | N | N | 220028359 | METHOTREXATE INTRATHECAL |
| 220009687 | 220012114 | null | 55 | Curative (C) | 2015-12-30 | 2016-01-05 | FEC | Y | N | 220028442 | VIDE |
| 220009688 | 220016555 | 1.61 | 78.4 | null | 2018-01-08 | 2018-01-08 | CARBOPLATIN + FLUOROURACIL | N | N | 220028561 | ABIRATERONE |
| 220009689 | 220003963 | 1.64 | 44.3 | Curative (C) | 2014-12-18 | 2014-12-18 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | N | N | 220028611 | IDARUBICIN + MITOXANTRONE + TRETINOIN |
| 220009690 | 220003963 | 1.73 | 73.6 | Palliative (P) | 2017-03-16 | 2017-03-16 | DABRAFENIB + TRAMETINIB | N | N | 220028611 | IPILIMUMAB |
| 220009691 | 220003964 | 1.82 | 82 | null | 2015-07-04 | 2015-07-05 | ATG + Busulfan + Fludarabine | 02 | N | 220028693 | CISPLATIN |
| 220009692 | 220003964 | 1.6 | null | null | null | 2017-11-10 | FLUDARABINE | null | null | 220028693 | METHOTREXATE HIGH DOSE |
| 220009693 | 220003964 | 1.65 | 0 | Curative (C) | 2016-10-19 | 2016-10-19 | Gemcitabine + Capecitabine | 02 | N | 220028693 | METHOTREXATE INTRATHECAL |
| 220009694 | 220003964 | null | 72.55 | Curative (C) | null | 2017-12-09 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | null | N | 220028693 | TRIPLE INTRATHECAL |
| 220009695 | 220003965 | null | 80 | Curative (C) | 2015-03-04 | 2015-03-04 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 220028966 | FLUDARABINE + MELPHALAN |
| 220009696 | 220003966 | null | 41.25 | Palliative (P) | null | 2013-08-17 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | N | 220028990 | CISPLATIN + FLUOROURACIL |
| 220009697 | 220003967 | 1.94 | 9.7 | Curative (C) | 2015-01-09 | 2015-01-09 | Folfirinox | null | null | 220029019 | CYTARABINE IT + METHOTREXATE |
| 220009698 | 220003968 | 1.65 | 65 | Curative (C) | 2016-11-04 | 2016-12-05 | FCR | N | N | 220029097 | ARSENIC TRIOXIDE + TRETINOIN |
| 220009699 | 220003968 | 1.5 | 58 | Disease modification (D) | null | 2016-01-20 | Temozolomide 150mg/m2 | N | N | 220029097 | BOSUTINIB |
| 220009700 | 220003968 | null | 114.5 | Curative (C) | 2014-09-18 | 2014-09-18 | ECarboX | N | N | 220029097 | IDARUBICIN |
| 220009701 | 220003968 | 1.53 | null | null | 2017-11-04 | 2017-11-16 | RUXOLITINIB | N | N | 220029097 | FLUDARABINE |
| 220009702 | 220003968 | null | 56.3 | Palliative (P) | 2017-09-01 | 2017-09-07 | Irinotecan + Modified De Gramont | N | N | 220029097 | PACLITAXEL |
| 220009703 | 220003968 | 0 | 73 | Curative (C) | 2015-10-29 | 2015-10-31 | Methotrexate intrathecal | 02 | N | 220029097 | TRIPLE INTRATHECAL |